Screening of 22q11.2DS Using Multiplex Ligation-Dependent Probe Amplification as an Alternative Diagnostic Method.

Sathiya Maran Siti Aisyah FatenSwee-Hua Erin LimKok-Song LaiWan Pauzi Wan IbrahimRavindran Ankathil Siew Hua Gan Huay Lin Tan

Published in: BioMed research international (2020)

The incidence of 22q11.2DS among patients with CHD in the east coast of Malaysia is 0.047. MLPA is a scalable and affordable alternative molecular diagnostic method in the screening of 22q11.2DS and can be routinely applied for the diagnosis of deletion syndromes.

Keyphrases

risk factors
high throughput
living cells